GLP-2 receptors in human disease: High expression in gastrointestinal stromal tumors and Crohn's disease

Molecular and Cellular Endocrinology

Volumn 364, Issue 1-2, 2012, Pages 46-53

  Körner, Meike ^a   Rehmann, Ruth ^a   Reubi, Jean Claude ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Crohn's disease; Gastrointestinal stromal tumor; GLP 2; Incretin receptors; Short bowel syndrome

Indexed keywords

GLUCAGON LIKE PEPTIDE 2; GLUCAGON LIKE PEPTIDE 2 RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; CROHN DISEASE; FEMALE; GASTROINTESTINAL TUMOR; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; MALE; MYENTERIC PLEXUS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ADULT; AGED; AUTORADIOGRAPHY; CROHN DISEASE; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; GENE EXPRESSION; GLUCAGON-LIKE PEPTIDE 2; HUMANS; INTESTINES; MIDDLE AGED; MYENTERIC PLEXUS; RECEPTORS, GLUCAGON; UP-REGULATION;

EID: 84867526563     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2012.08.008     Document Type: Article

References (44)

1. Abad C., Juarranz Y., Martinez C., Arranz A., Rosignoli F., García-Gómez M., Leceta J., Gomariz R.P. CDNA array analysis of cytokines, chemokines, and receptors involved in the development of TNBS-induced colitis: homeostatic role of VIP. Inflamm. Bowel Dis. 2005, 11:674-684.
2. Alavi K., Schwartz M.Z., Palazzo J.P., Prasad R. Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2. J. Pediatr. Surg. 2000, 35:847-851.
3. Ardeleanu C., Bussolati G. Telocytes are the common cell of origin of both PEComas and GISTs: an evidence-supported hypothesis. J. Cell Mol. Med. 2011, 15:2569-2574.
4. 125I]labeled ligands with Amersham Hyperfilm beta-max. Neurosci. Lett. 1989, 104:171-177.
5. Bengi G., Kayahan H., Akarsu M., Aysal A., Sagol ö., Meral M., Akpinar H. Does glucagon like peptide-2 receptor expression have any effect on the development of human colorectal cancer?. Turk. J. Gastroenterol. 2011, 22:388-394.
6. Booth C., Booth D., Williamson S., Demchyshyn L.L., Potten C.S. Teduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage. Cell Prolif. 2004, 37:385-400.
7. Buchman A.L., Katz S., Fang J.C., Bernstein C.N., Abou-Assi S.G., Group T.S. Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease. Inflamm. Bowel Dis. 2010, 16:962-973.
8. Christ E., Wild D., Forrer F., Brändle M., Sahli R., Clerici T., Gloor B., Martius F., Maecke H.R., Reubi J.C. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J. Clin. Endocrinol. Metab. 2009, 94:4398-4405.
9. de Heer J., Pedersen J., Orskov C., Holst J.J. The alpha cell expresses glucagon-like peptide-2 receptors and glucagon-like peptide-2 stimulates glucagon secretion from the rat pancreas. Diabetologia 2007, 50:2135-2142.
10. Drucker D.J., Erlich P., Asa S.L., Brubaker P.L. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc. Natl. Acad. Sci. USA 1996, 93:7911-7916.
11. Gleeson M.H., Bloom S.R., Polak J.M., Henry K., Dowling R.H. Endocrine tumour in kidney affecting small bowel structure, motility, and absorptive function. Gut 1971, 12:773-782.
12. Guan X., Karpen H.E., Stephens J., Bukowski J.T., Niu S., Zhang G., Stoll B., Finegold M.J., Holst J.J., Hadsell D., Nichols B.L., Burrin D.G. GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology 2006, 130:150-164.
13. Hartmann B., Thulesen J., Hare K.J., Kissow H., Orskov C., Poulsen S.S., Holst J.J. Immunoneutralization of endogenous glucagon-like peptide-2 reduces adaptive intestinal growth in diabetic rats. Regul. Pept. 2002, 105:173-179.
14. Iakoubov R., Lauffer L.M., Trivedi S., Kim Y.I., Brubaker P.L. Carcinogenic effects of exogenous and endogenous glucagon-like peptide-2 in azoxymethane-treated mice. Endocrinology 2009, 150:4033-4043.
15. Jeppesen P.B., Gilroy R., Pertkiewicz M., Allard J.P., Messing B., O'Keefe S.J. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut 2011, 60:902-914.
16. Kindblom L.G., Remotti H.E., Aldenborg F., Meis-Kindblom J.M. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am. J. Pathol. 1998, 152:1259-1269.
17. Koehler J.A., Harper W., Barnard M., Yusta B., Drucker D.J. Glucagon-like peptide-2 does not modify the growth or survival of murine or human intestinal tumor cells. Cancer Res. 2008, 68:7897-7904.
18. Koehler J.A., Yusta B., Drucker D.J. The HeLa cell glucagon-like peptide-2 receptor is coupled to regulation of apoptosis and ERK1/2 activation through divergent signaling pathways. Mol. Endocrinol. 2005, 19:459-473.
19. Körner M., Eltschinger V., Waser B., Schonbrunn A., Reubi J.C. Value of immunohistochemistry for somatostatin receptor subtype sst2A in cancer tissues: lessons from the comparison of anti-sst2A antibodies with somatostatin receptor autoradiography. Am. J. Surg. Pathol. 2005, 29:1642-1651.
20. Körner M., Stöckli M., Waser B., Reubi J.C. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J. Nucl. Med. 2007, 48:736-743.
21. Körner M., Waser B., Reubi J.C., Miller L.J. CCK2 receptor splice variant with intron 4 retention in human gastrointestinal and lung tumors. J. Cell Mol. Med. 2010, 14:933-943.
22. Körner M., Waser B., Schonbrunn A., Perren A., Reubi J.C. Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting. Am. J. Surg. Pathol. 2012, 36:242-252.
23. Kwekkeboom D.J., de Herder W.W., Kam B.L., van Eijck C.H., van Essen M., Kooij P.P., Feelders R.A., van Aken M.O., Krenning E.P. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J. Clin. Oncol. 2008, 26:2124-2130.
24. Maecke H.R., Reubi J.C. Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment. J. Nucl. Med. 2011, 52:841-844.
25. Masur K., Schwartz F., Entschladen F., Niggemann B., Zaenker K.S. DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cells. Regul. Pept. 2006, 137:147-155.
26. Mayo K.E., Miller L.J., Bataille D., Dalle S., Goke B., Thorens B., Drucker D.J. International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol. Rev. 2003, 55:167-194.
27. Miettinen M., Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin. Diagn. Pathol. 2006, 23:70-83.
28. 125I-labeled ligands in quantitative autoradiography. Neurosci. Lett. 1987, 81:345-350.
29. Munroe D.G., Gupta A.K., Kooshesh F., Vyas T.B., Rizkalla G., Wang H., Demchyshyn L., Yang Z.J., Kamboj R.K., Chen H., McCallum K., Sumner-Smith M., Drucker D.J., Crivici A. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc. Natl. Acad. Sci. USA 1999, 96:1569-1573.
30. Ørskov C., Hartmann B., Poulsen S., Thulesen J., Hare K.J., Holst J.J. GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regul. Pept. 2005, 124:105-112.
31. Portha B., Tourrel-Cuzin C., Movassat J. Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass. Exp. Diabetes Res. Epub. 2011, 2011:376509.
32. Reubi J.C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr. Rev. 2003, 24:389-427.
33. Reubi J.C., Körner M., Waser B., Mazzucchelli L., Guillou L. High expression of peptide receptors as a novel target in gastrointestinal stromal tumours. Eur. J. Nucl. Med. Mol. Imaging 2004, 31:803-810.
34. Reubi J.C., Mazzucchelli L., Laissue J.A. Intestinal vessels express a high density of somatostatin receptors in human inflammatory bowel disease. Gastroenterology 1994, 106:951-959.
35. Reubi J.C., Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur. J. Nucl. Med. Mol. Imaging 2003, 30:781-793.
36. Reubi J.C., Waser B., Friess H., Büchler M., Laissue J.A. Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma. Gut 1998, 42:546-550.
37. Sams A., Hastrup S., Andersen M., Thim L. Naturally occurring glucagon-like peptide-2 (GLP-2) receptors in human intestinal cell lines. Eur. J. Pharmacol. 2006, 532:18-23.
38. Sigalet D.L., Wallace L.E., Holst J.J., Martin G.R., Kaji T., Tanaka H., Sharkey K.A. Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 293:G211-G221.
39. Thulesen J., Hartmann B., Hare K.J., Kissow H., Ørskov C., Holst J.J., Poulsen S.S. Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice. Gut 2004, 53:1145-1150.
40. Thulesen J., Hartmann B., Orskov C., Jeppesen P.B., Holst J.J., Poulsen S.S. Potential targets for glucagon-like peptide 2 (GLP-2) in the rat: distribution and binding of i.v. injected (125)I-GLP-2. Peptides 2000, 21:1511-1517.
41. Sobin L.H., Gospodarowicz M.K., Wittekind C. TNM Classification of Malignant Tumors 2010, Wiley-Blackwell, Chichester, UK. seventh ed.
42. Wallis K., Walters J.R., Gabe S. Short bowel syndrome: the role of GLP-2 on improving outcome. Curr. Opin. Clin. Nutr. Metab. Care 2009, 12:526-532.
43. Yusta B., Boushey R.P., Drucker D.J. The glucagon-like peptide-2 receptor mediates direct inhibition of cellular apoptosis via a cAMP-dependent protein kinase-independent pathway. J. Biol. Chem. 2000, 275:35345-35352.
44. Yusta B., Huang L., Munroe D., Wolff G., Fantaske R., Sharma S., Demchyshyn L., Asa S.L., Drucker D.J. Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology 2000, 119:744-755.